Calendario›ACHV›custirsen

custirsen

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Ensayo de ACHIEVE LIFE SCIENCES, INC. en Cancer de prostata.

Más ensayos de: Cáncer de próstata.

Fase

Fase 2

Estado

Completado

Participantes

70

previstos

Centros

10

Fin del objetivo primario

oct 2010

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en jul 2006.

Qué mide

Seguridad y tolerabilidad de Custirsen (OGX-011) en combinacion con docetaxel/prednisona o mitoxantrona/prednisona como quimioterapia de segunda linea. (Subjects were followed for safety from enrollment for up to 8 months (9 three-week cycles plus 30 days after end of treatment)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is for patients with cancer of the prostate gland that has metastasized or spread outside the prostate to other parts of the body. Patients have already been treated with a drug called docetaxel or Taxotere® (with or without the addition of a steroid called prednisone) some time in the recent past. They either did not respond to this therapy or responded to this therapy, but now the cancer is progressing (growing larger or has spread to other areas of the body). Custirsen (OGX-011) is an experimental drug that has been shown to increase the effectiveness of chemotherapy in several kinds of tumors, including prostate cancer. Both docetaxel and mitoxantrone have anticancer activity in prostate and are approved by Health Canada and the Food and Drug Administration for the treatment of patients with prostate cancer.

Más ensayos de ACHV

Todos los de ACHV, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00327340), actualizada en oct 2012.